Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4309236 | 0.85 | MC4R (0.43) | SCD | |
| SCHEMBL4312795 | 0.83 | SCD (0.43) | SCD | |
| SCHEMBL4311710 | 0.82 | AKR1B10 (0.49) | — | |
| SCHEMBL4307328 | 0.82 | MTNR1A (0.40) | — | |
| SCHEMBL4312648 | 0.79 | MTNR1A (0.36) | — | |
| SCHEMBL4315289 | 0.78 | MTNR1A (0.38) | — | |
| SCHEMBL6047784 | 0.77 | MTNR1A (0.40) | TSPO | |
| SCHEMBL4321767 | 0.77 | MTNR1A (0.43) | — | |
| SCHEMBL4305278 | 0.76 | LYN (0.42) | TSPO | |
| SCHEMBL4320915 | 0.76 | MTNR1A (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | claimed |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN3, KCNN1, KCNN2 | SCD 4403/4885TSPO 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.